NodThera Announces Positive Phase 1 Study Readouts for the NLRP3 Inflammasome Inhibitors NT-0796 and NT-0249

/PRNewswire/ -- NodThera, a clinical-stage biotechnology company developing a new class of potent and selective oral, small molecule NLRP3 inflammasome...

Related Keywords

Adam Keeney ,Calan Watt , ,Chief Executive Officer ,Nodthera ,